Activation of the AMPK/Sirt1 pathway by a leucine–metformin combination increases insulin sensitivity in skeletal muscle, and stimulates glucose and lipid metabolism and increases life span in Caenorhabditis elegans

Metabolism: Clinical and Experimental

Volumn 65, Issue 11, 2016, Pages 1679-1691

  Banerjee, Jheelam ^a   Bruckbauer, Antje ^a   Zemel, Michael B ^a  

^a NuSirt Sciences Inc   (United States)

Author keywords

AMPK; Insulin sensitivity; Leucine; Metformin; Sirt1

Indexed keywords

CREB REGULATED TRANSCRIPTION COACTIVATOR 2 PROTEIN; GLUCOSE; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEUCINE; LIPID; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN; SIRTUIN 1; UNCLASSIFIED DRUG; ACETYL COENZYME A CARBOXYLASE; ANTIDIABETIC AGENT; CRTC2 PROTEIN, MOUSE; FATTY ACID; TRANSCRIPTION FACTOR;

ADULT; ANIMAL CELL; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG POTENTIATION; EC50; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATTY ACID OXIDATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; GLYCOGEN SYNTHESIS; INSULIN SENSITIVITY; LIFESPAN; LIPID METABOLISM; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ACETYL-COA CARBOXYLASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CAENORHABDITIS ELEGANS; CELL LINE; DRUG SYNERGISM; FATTY ACIDS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LEUCINE; LIPID METABOLISM; METFORMIN; MICE; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION; SIRTUIN 1; TRANSCRIPTION FACTORS;

EID: 84979055707     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.06.011     Document Type: Article

References (50)

1. [1] Viollet, B, Guigas, B, Sanz Garcia, N, Leclerc, J, Foretz, M, Andreelli, F, Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 122 (2012), 253–270.
2. [2] Pawlyk, AC, Giacomini, KM, McKeon, C, Shuldiner, AR, Florez, JC, Metformin pharmacogenomics: current status and future directions. Diabetes 63 (2014), 2590–2599.
3. [3] Nathan, DM, Diabetes advances in diagnosis and treatment. JAMA, 314, 2015, 1052.
4. [4] Brietzke, SA, Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am 99 (2015), 87–106.
5. [5] Lim, PC, Chong, CP, What's next after metformin? Focus on sulphonylurea : add-on or combination therapy. Pharm Pract (Granada), 13, 2015, 606.
6. [6] Lan, F, Cacicedo, JM, Ruderman, N, Ido, Y, SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1: possible role in AMP-activated protein kinase activation. J Biol Chem 283 (2008), 27628–27635.
7. [7] Cantó, C, Gerhart-Hines, Z, Feige, JN, Lagouge, M, Noriega, L, Milne, JC, et al. AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature 458 (2009), 1056–1060.
8. [8] Sun, C, Zhang, F, Ge, X, Yan, T, Chen, X, Shi, X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 6 (2007), 307–319.
9. [9] Ruderman, NB, Carling, D, Prentki, M, Cacicedo, JM, AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123 (2013), 2764–2772.
10. [10] Banks, AS, Kon, N, Knight, C, Matsumoto, M, Gutiérrez-Juárez, R, Rossetti, L, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8 (2008), 333–341.
11. [11] Bruckbauer, A, Zemel, MB, Synergistic effects of polyphenols and methylxanthines with leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes. PLoS One, 9, 2014, e89166.
12. [12] Fu, L, Bruckbauer, A, Li, F, Cao, Q, Cui, X, Wu, R, et al. Leucine amplifies the effects of metformin on insulin sensitivity and glycemic control in diet-induced obese mice. Metabolism 64 (2015), 845–856.
13. [13] Stiernagle, T, Maintenance of C. elegans. WormBook, 1–11, 2006.
14. [14] Ruderman, NB, Xu, XJ, Nelson, L, Cacicedo, JM, Saha, AK, Lan, F, et al. AMPK and SIRT1: a long-standing partnership?. Am J Physiol Endocrinol Metab 298 (2010), E751–E760.
15. [15] Pfluger, PT, Herranz, D, Velasco-miguel, S, Serrano, M, Tscho, MH, Sirt1 protects against high-fat diet-induced metabolic damage. PNAS 105 (2008), 9793–9798.
16. [16] Gauthier, M-S, O'Brien, EL, Bigornia, S, Mott, M, Cacicedo, JM, Xu, JX, et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun 404 (2011), 382–387.
17. [17] Liu, Y, Wan, Q, Guan, Q, Gao, L, Zhao, J, High-fat diet feeding impairs both the expression and activity of AMPKa in rats’ skeletal muscle. Biochem Biophys Res Commun 339 (2006), 701–707.
18. [18] Caton, PW, Kieswich, J, Yaqoob, MM, Holness, MJ, Sugden, MC, Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. Diabetes Obes Metab 13 (2011), 1097–1104.
19. [19] Bosi, E, Metformin–the gold standard in type 2 diabetes: what does the evidence tell us?. Diabetes Obes Metab 11:Suppl. 2 (2009), 3–8.
20. [20] Caton, PW, Nayuni, NK, Kieswich, J, Khan, NQ, Yaqoob, MM, Corder, R, Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J Endocrinol 205 (2010), 97–106.
21. [21] Zheng, Z, Chen, H, Li, J, Li, T, Zheng, B, Zheng, Y, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 61 (2012), 217–228.
22. [22] Bruckbauer, A, Zemel, MB, Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab Syndr Obes 6 (2013), 93–102.
23. [23] Foretz, M, Hébrard, S, Leclerc, J, Zarrinpashneh, E, Soty, M, Mithieux, G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120 (2010), 2355–2369.
24. [24] Liang, C, Curry, BJ, Brown, PL, Zemel, MB, Leucine modulates mitochondrial biogenesis and SIRT1-AMPK signaling in C2C12 myotubes. J Nutr Metab, 2014, 2014, 239750.
25. [25] Hou, X, Xu, S, Maitland-Toolan, KA, Sato, K, Jiang, B, Ido, Y, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283 (2008), 20015–20026.
26. [26] Boura-Halfon, S, Zick, Y, Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 296 (2009), E581–E591.
27. [27] Yoshizaki, T, Milne, JC, Imamura, T, Schenk, S, Sonoda, N, Babendure, JL, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 29 (2009), 1363–1374.
28. [28] Shibata, T, Takaguri, A, Ichihara, K, Satoh, K, Inhibition of the TNF-α-induced serine phosphorylation of IRS-1 at 636/639 by AICAR. J Pharmacol Sci 122 (2013), 93–102.
29. [29] Weigert, C, Hennige, AM, Brischmann, T, Beck, A, Moeschel, K, Scha, M, et al. The phosphorylation of Ser 318 of insulin receptor substrate 1 is not per se inhibitory in skeletal muscle cells but is necessary to trigger the attenuation of the insulin-stimulated signal *. J Biol Chem 280 (2005), 37393–37399.
30. [30] D'Alessandris, C, Lauro, R, Presta, I, Sesti, G, C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. Diabetologia 50 (2007), 840–849.
31. [31] Prada, PO, Zecchin, HG, Gasparetti, AL, Torsoni, MA, Ueno, M, Hirata, AE, et al. Western diet modulates insulin signaling, c-Jun N-terminal kinase activity, and insulin receptor substrate-1ser307 phosphorylation in a tissue-specific fashion. Endocrinology 146 (2005), 1576–1587.
32. [32] Von Wilamowitz-Moellendorff, A, Hunter, RW, García-Rocha, M, Kang, L, López-Soldado, I, Lantier, L, et al. Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis. Diabetes 62 (2013), 4070–4082.
33. [33] Sharabi, K, Tavares, CDJ, Rines, AK, Puigserver, P, Molecular pathophysiology of hepatic glucose production. Mol Aspects Med 46 (2015), 21–33.
34. [34] Horike, N, Sakoda, H, Kushiyama, A, Ono, H, Fujishiro, M, Kamata, H, et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3beta and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J Biol Chem 283 (2008), 33902–33910.
35. [35] Zhang, BB, Zhou, G, Li, C, AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9 (2009), 407–416.
36. [36] Fu, L, Bruckbauer, A, Li, F, Cao, Q, Cui, X, Wu, R, et al. Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice. Metabolism 64 (2015), 1426–1434.
37. [37] Zheng, J, Greenway, FL, Caenorhabditis elegans as a model for obesity research. Int J Obes (Lond) 36 (2012), 186–194.
38. [38] Choi, SS, High glucose diets shorten lifespan of Caenorhabditis elegans via ectopic apoptosis induction. Nutr Res Pract, 5, 2011, 214.
39. [39] Schlotterer, A, Kukudov, G, Bozorgmehr, F, Hutter, H, Du, X, Oikonomou, D, et al. C elegans as model for the study of high glucose-mediated life span reduction. Diabetes 58 (2009), 2450–2456.
40. [40] Lee, S-J, Murphy, CT, Kenyon, C, Glucose shortens the life span of C. elegans by downregulating DAF-16/FOXO activity and aquaporin gene expression. Cell Metab 10 (2009), 379–391.
41. [41] Elango, R, Chapman, K, Rafii, M, Ball, RO, Pencharz, PB, Determination of the tolerable upper intake level of leucine in acute dietary studies in young men. Am J Clin Nutr 96 (2012), 759–767.
42. [42] Gabr, RQ, Padwal, RS, Brocks, DR, Determination of metformin in human plasma and urine by high-performance liquid chromatography using small sample volume and conventional octadecyl silane column. J Pharm Pharm Sci 13 (2010), 486–494.
43. [43] He, L, Wondisford, FE, Metformin action: concentrations matter. Cell Metab 21 (2015), 159–162.
44. [44] Ouyang, J, Parakhia, RA, Ochs, RS, Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 286 (2011), 1–11.
45. [45] Vytla, VS, Ochs, RS, Metformin increases mitochondrial energy formation in L6 muscle cell cultures. J Biol Chem 288 (2013), 20369–20377.
46. [46] Zang, M, Zuccollo, A, Hou, X, Nagata, D, Walsh, K, Herscovitz, H, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279 (2004), 47898–47905.
47. [47] Lee, SK, Lee, JO, Kim, JH, Kim, SJ, You, GY, Moon, JW, et al. Metformin sensitizes insulin signaling through AMPK-mediated PTEN down-regulation in preadipocyte 3T3-L1 cells. J Cell Biochem 112 (2011), 1259–1267.
48. [48] Owen, MR, Doran, E, Halestrap, AP, Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:Pt 3 (2000), 607–614.
49. [49] Woods, A, Johnstone, SR, Dickerson, K, Leiper, FC, Fryer, LGD, Neumann, D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13 (2003), 2004–2008.
50. [50] Gowans, GJ, Hawley, SA, Ross, FA, Hardie, DG, AMP is a true physiological regulator of AMP-activated protein kinase by both allosteric activation and enhancing net phosphorylation. Cell Metab 18 (2013), 556–566.